Novartis Plays Access Card As Kisqali Gets EU Approval
Executive Summary
The Swiss major says that it 'eagerly awaits' a NICE decision on its advanced breast cancer treatment so patients in England and Wales get access quickly.
You may also be interested in...
Novartis' Kisqali Impresses In Premenopausal Breast Cancer As Market Crowds
Updated data from the MONALEESA-7 study shows the extent of its progression-free survival benefit in premenopausal women with advanced breast cancer; supplemental filings are planned.
Novartis Sets 'Flexible Pricing' For Kisqali To Compete Against Pfizer's Ibrance
Novartis has packaged and priced Kisqali – the second CDK4/6 inhibitor approved in the US – to compete with Pfizer's Ibrance, which made the mechanism of action the standard of care in untreated metastatic HR+/HER2- breast cancer.
BenevolentAI Still Bullish As CEO Shields Steps Down
BenevolentAI has added Merck KGaA to its list of partners but the UK firm is looking for a new CEO after Joanna Shields decided to leave as a major restructuring continues.